+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Neurofibromatosis Treatment Market: By Type, By Drug Class & Geography - Forecast 2016-2021

  • ID: 3973954
  • Report
  • 157 pages
  • IndustryARC
1 of 3
Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue. These formed tumors may develop anywhere in the nervous system of the victim, which may include the brain, spinal cord and nerves. Neurofibromatosis is usually diagnosed in childhood or early adulthood. The tumors are noncancerous (benign) in most of the cases, but in some cases these tumors become cancerous (malignant) tumors. People suffering with neurofibromatosis often experience only mild symptom and effects may range from hearing loss, learning impairment, and heart and blood vessel (cardiovascular) complications to severe disability due to nerve compression by tumors, loss of vision and severe pain. There is no specific treatment for neurofibromatosis, but treatment aims to maximize healthy growth and development and to manage complications as soon as they arise. When neurofibromatosis causes large tumors or tumors that press on a nerve, surgery may help ease symptoms.

Geographically North America dominated global neurofibromatosis treatment market, due to advanced medical infrastructure and approximately half of the world’s procedures being done in the U.S. because of high medical reimbursement facilities, and technological advancement. North America was followed by Europe and Asia-Pacific as second and third largest market for neurofibromatosis treatment. Asia Pacific is projected to have fastest growth, owing to rapidly increasing population, rise in consumer awareness, favourable government policies, modernization of healthcare infrastructure, and growing medical tourism industry in developing nations such as China, and India in this region.

This report identifies the Neurofibromatosis Treatment market size in for the year 2016-2021, and forecast of the same for year 2021. It also highlights the potential growth opportunities in the coming years, while also reviewing the market drivers, restraints, growth indicators, challenges, market dynamics, competitive landscape, and other key aspects with respect to Neurofibromatosis Treatment market.

This report is segmented into four major drug class. Some of the major drug class covered in this report are as follows: Drug therapy, Surgery, Radiation therapy and Chemotherapy and Others
This report is segmented into three major type. Some of the major type covered in this report are as follows:NF1, NF2, Schwannomatosis
This is report has been further segmented into major regions, which includes detailed analysis of each region such as North America, Europe, Asia-Pacific (APAC) and Rest of the World (RoW) covering all the major country level markets for Neurofibromatosis Treatment in each of the region.

This report identifies all the major companies operating in the global Neurofibromatosis Treatment market. Some of the major companies’ profiles in detail are as follows:

Texas Neurofibromatosis Foundation
University of Alabama at Birmingham
Erasmus Medical Center
Assistance Publique - Hopitaux de Paris
Indiana University
Please Note: The report is to be delivered in 1-2 working days after an order is placed.
Note: Product cover images may vary from those shown
2 of 3
1. Neurofibromatosis Treatment– Market Overview

2. Executive Summary

3. Market Landscape
3.1. Market Share Analysis
3.2. Comparative Analysis
3.2.1. Product Benchmarking
3.2.2. End User Profiling
3.2.3. Top 5 Financials Analysis

4. Neurofibromatosis Treatment– Market Forces
4.1. Drivers
4.1.1. Rising population neurofibromatosis disease
4.1.2. Potential risk factor of hearing loss during surgery
4.2. Opportunities
4.3. Challenges
4.4. Porter’s Five Forces Analysis
4.4.1. Bargaining Power of Suppliers
4.4.2. Bargaining Power of Buyers
4.4.3. Threat of New Entrants
4.4.4. Threat of Substitutes
4.4.5. Degree of Competition

5. Neurofibromatosis Treatment– Strategic Analysis
5.1. Value Chain Analysis
5.2. Pricing Analysis
5.3. Opportunities Analysis
5.4. Product/Market Life Cycle Analysis
5.5. Suppliers and Distributors

6. Neurofibromatosis Treatment Market, By Type
6.1. NF1
6.2. NF2
6.3. Schwannomatosis

7. Neurofibromatosis Treatment Market, By Drug class
7.1. Drug therapy
7.2. Surgery
7.3. Radiation therapy
7.4. Chemotherapy
7.5. Others

8. Neurofibromatosis Treatment Market, By Geography
8.1. Europe
8.1.1. Germany
8.1.2. France
8.1.3. Italy
8.1.4. Spain
8.1.5. Russia
8.1.6. U.K.
8.1.7. Rest of Europe
8.2. Asia Pacific
8.2.1. China
8.2.2. India
8.2.3. Japan
8.2.4. South Korea
8.2.5. Rest of Asia-Pacific
8.3. North America
8.3.1. U.S.
8.3.2. Canada
8.3.3. Mexico
8.4. Rest of the World (RoW)
8.4.1. Brazil
8.4.2. Rest of RoW

9. Neurofibromatosis Treatment– Market Entropy
9.1. Expansion
9.2. Technological Developments
9.3. Merger & Acquisitions, and Joint Ventures
9.4. Supply- Contract

10. Company Profiles
10.1. Texas Neurofibromatosis Foundation
10.2. University of Alabama at Birmingham
10.3. Erasmus Medical Center
10.4. Assistance Publique - Hopitaux de Paris
10.5. Indiana University
10.6. Pfizer
10.7. GL Pharm Tech Corporation
10.8. Hôpitaux de ParisOthers
10.9. GlaxoSmithKline
10.10. Neuro-Hitech, Inc.
*More than 40 Companies are profiled in this Research Report, Complete List available on Request*
"*Financials would be provided on a best efforts basis for private companies"

11. Appendix
11.1. Abbreviations
11.2. Sources
11.3. Research Methodology
11.4. Bibliography
11.5. Compilation of expert Insights
11.6. Disclaimer
Note: Product cover images may vary from those shown
3 of 3


4 of 3